Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies
Recommended Citation
Zane LT, Chanda S, Jarnagin K, Nelson DB, Spelman L, Stein Gold LF. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy 2016; 8(8):853-866.
Document Type
Article
Publication Date
7-1-2016
Publication Title
Immunotherapy
Abstract
Atopic dermatitis (AD), a chronic, relapsing, inflammatory skin disease that is characterized by intense pruritus and eczematous lesions with up to 90% of patients presenting with mild to moderate disease. Current topical treatments for AD have not changed in over 15 years and are associated with safety concerns. In AD, overactivity of phosphodiesterase 4 (PDE4), leads to inflammation and disease exacerbation. Crisaborole Topical Ointment, 2%, is a novel, nonsteroidal, topical anti-inflammatory PDE4 inhibitor currently being investigated for the treatment of mild to moderate AD. Preliminary studies in children and adults demonstrated favorable efficacy and safety profiles. Crisaborole may represent an anti-inflammatory option that safely minimizes the symptoms and severity of AD and that can be used for both acute and long-term management.
Medical Subject Headings
Administration, Topical; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Child; Clinical Trials as Topic; Dermatitis, Atopic; Humans; Ointments; Phosphodiesterase 4 Inhibitors
PubMed ID
27283509
Volume
8
Issue
8
First Page
853
Last Page
866
